What the FDA labels say about taking them together
Bromocriptine and pasireotide
Pasireotide's FDA label of July 16, 2024 names bromocriptine in its drug interactions section; the bromocriptine labels PlainMeds reads (2) do not name pasireotide. The pasireotide label: “Consider additional monitoring. Bromocriptine: Consider bromocriptine dose reduction.”
Check it at the source: the bromocriptine FDA label on DailyMed (effective July 27, 2026, ANI Pharmaceuticals, Inc.); the pasireotide FDA label on DailyMed (effective July 16, 2024, Recordati Rare Diseases, Inc.).
What does the bromocriptine label say about pasireotide?
Bromocriptine's label (effective July 27, 2026) and its 1 other brand-application label do not name pasireotide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Bromocriptine Mesylate), ANI Pharmaceuticals, Inc., effective July 27, 2026 (SPL set 17f3a343-1782-4799-95ba-31dfe93be2cf), via openFDA; the full label on DailyMed
What does the pasireotide label say about bromocriptine?
Pasireotide label, drug interactionsConsider additional monitoring. ( 7.2 ) Bromocriptine: Consider bromocriptine dose reduction.
Source: FDA drug label (Signifor LAR), Recordati Rare Diseases, Inc., effective July 16, 2024 (SPL set a0aad470-3f38-af97-e053-2995a90a383a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bromocriptine | Pasireotide | |
|---|---|---|
| Labeled for | Parkinson's disease, Type 2 diabetes | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.61 per tablet 2.5 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once